Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097

• Published in: eLife 2016-11, Vol.5
• Main Authors: Jeay, Sébastien, Gaulis, Swann, Ferretti, Stéphane, Bitter, Hans, Ito, Moriko, Valat, Thérèse, Murakami, Masato, Ruetz, Stephan, Guthy, Daniel A, Rynn, Caroline, Jensen, Michael R, Wiesmann, Marion, Kallen, Joerg, Furet, Pascal, Gessier, François, Holzer, Philipp, Masuya, Keiichi, Würthner, Jens, Halilovic, Ensar, Hofmann, Francesco, Sellers, William R, Graus Porta, Diana
• Format: Article
• Language: English
• Subjects: Gene expression; Human Biology and Medicine; Mutation; p53 Protein; Response rates
• ISSN: 2050-084X; 2050-084X
• DOI: 10.7554/eLife.19317

Sonkin’s approach would require multiple technologies to measure p53 gene expression and p53 copy number in addition to sequencing the full-length of p53 for mutation status. [...]we and others have utilized p53 mutation status (and not p53 expression, copy number, and mutation status) in the clinic, or have explored the use of gene expression-based signatures due to the complexity required in Sonkin’s approach. [...]10/12 reannotated cell lines in the ‘validation set’ harbor p53 mutations (shown in red in Table 1). [...]we selected these cell lines in both sets that were miscalled for their p53 mutation status only, as it is currently implemented in the clinic, to correct our original manuscript (i.e. 13 mutated cells in the ‘discovery set’ and 10 mutated cells in the ‘validation set’ shown in red in Table 1) and not Sonkin’s reannotation (i.e. 29 and 12 cell lines in the ‘discovery set’ and ‘validation set’, respectively). (Figure 2E): 76% for the 13-gene signature vs. 59% for the 215-feature set vs. 63% for TP53 mutation status. [...]these results show that the 13-gene signature provides an improvement in response prediction to drug treatment over both the TP53 mutation status and the larger signature consisting of 215 significant features.’ is now ‘… and the larger signature consisting of 215 significant features. [...]these results suggest that the 13-gene signature has utility in TP53 wild-type genetic backgrounds.